The Top 5 Biosimilars Articles for the Week of November 20
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of November 20.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 20.
Number 5: The European Medicines Agency will move to Amsterdam, Netherlands, after European ministers voted on the agency’s post-Brexit relocation.
Number 4: A recently published case study shows that a non-medical switch to biosimilar infliximab was associated with a rapid loss of treatment response in multiple patients with Behçet's disease.
Number 3: Samsung Bioepis has been granted the first European marketing authorization for a trastuzumab biosimilar, referenced on Herceptin.
Number 2: Stacie Phan, president of the Biosimilars Forum, explains the critical need for US physicians to gain better education on biosimilar therapies.
Number 1: Swiss drug maker Roche has sued biosimilar developer Pfizer over its proposed trastuzumab biosimilar.
Finally, last week, our e-newsletter asked whether you think that the so-called “nocebo” effect adequately explains patients switching away from biosimilars. To view results of the poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
